Stock 2696 SHANGHAI HENLIUS BIOTECH, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Shanghai Henlius Biotech, Inc.

Equities

2696

CNE100003N76

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:35 2024-05-22 am EDT 		5-day change 1st Jan Change
18.84 HKD +4.67% Intraday chart for Shanghai Henlius Biotech, Inc. -.--% +35.54%
May. 24 Organon, Henlius' Denosumab Biosimilar HLX14 Gets European Validation MT
May. 24 Henlius' EU Marketing Application for Denosumab Biosimilar Accepted and Validated by Regulator MT

Strengths

  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The valuation of the company is particularly high given the cash flows generated by its activity.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
SHANGHAI HENLIUS BIOTECH, INC. Stock Shanghai Henlius Biotech, Inc.
+35.54% 1.31B -
CSL LIMITED Stock CSL Limited
+0.82% 91.94B
A-
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
-1.32% 38.74B
A-
UCB Stock UCB
+63.75% 26.66B
A
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-12.88% 15.32B
C
INCYTE CORPORATION Stock Incyte Corporation
-5.75% 13.3B
B-
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-11.38% 11.65B
D+
ALTEOGEN INC. Stock ALTEOGEN Inc.
+173.10% 10.37B
D
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-49.84% 10.12B
B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+3.00% 9.06B
B+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
  1. Stock Market
  2. Equities
  3. 2696 Stock
  4. Ratings Shanghai Henlius Biotech, Inc.